BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 36883613)

  • 1. Dual antiplatelet therapy de-escalation in acute coronary syndrome: an individual patient meta-analysis.
    Kang J; Rizas KD; Park KW; Chung J; van den Broek W; Claassens DMF; Choo EH; Aradi D; Massberg S; Hwang D; Han JK; Yang HM; Kang HJ; Chang K; Ten Berg JM; Sibbing D; Koo BK; Kim HS
    Eur Heart J; 2023 Apr; 44(15):1360-1370. PubMed ID: 36883613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. De-escalation of dual antiplatelet therapy for patients with acute coronary syndrome after percutaneous coronary intervention: a systematic review and network meta-analysis.
    De Filippo O; Piroli F; Bruno F; Bocchino PP; Saglietto A; Franchin L; Angelini F; Gallone G; Rizzello G; Ahmad M; Gasparini M; Chatterjee S; De Ferrari GM; D'Ascenzo F
    BMJ Evid Based Med; 2024 May; 29(3):171-186. PubMed ID: 38242567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial.
    Kim HS; Kang J; Hwang D; Han JK; Yang HM; Kang HJ; Koo BK; Rhew JY; Chun KJ; Lim YH; Bong JM; Bae JW; Lee BK; Park KW;
    Lancet; 2020 Oct; 396(10257):1079-1089. PubMed ID: 32882163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with acute coronary syndrome: a meta-analysis.
    Tavenier AH; Mehran R; Chiarito M; Cao D; Pivato CA; Nicolas J; Beerkens F; Nardin M; Sartori S; Baber U; Angiolillo DJ; Capodanno D; Valgimigli M; Hermanides RS; van 't Hof AWJ; Ten Berg JM; Chang K; Kini AS; Sharma SK; Dangas G
    Eur Heart J Cardiovasc Pharmacother; 2022 Aug; 8(5):492-502. PubMed ID: 34459481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Unguided De-Escalation Versus Guided Selection of Dual Antiplatelet Therapy After Acute Coronary Syndrome: A Systematic Review and Network Meta-Analysis.
    Kuno T; Fujisaki T; Shoji S; Sahashi Y; Tsugawa Y; Iwagami M; Takagi H; Briasoulis A; Deharo P; Cuisset T; Latib A; Kohsaka S; Bhatt DL
    Circ Cardiovasc Interv; 2022 Aug; 15(8):e011990. PubMed ID: 35899618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
    Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Holdt L; Felix SB; Parma R; Klopotowski M; Schwinger RHG; Rieber J; Huber K; Neumann FJ; Koltowski L; Mehilli J; Huczek Z; Massberg S;
    Lancet; 2017 Oct; 390(10104):1747-1757. PubMed ID: 28855078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial.
    Kim CJ; Park MW; Kim MC; Choo EH; Hwang BH; Lee KY; Choi YS; Kim HY; Yoo KD; Jeon DS; Shin ES; Jeong YH; Seung KB; Jeong MH; Yim HW; Ahn Y; Chang K;
    Lancet; 2021 Oct; 398(10308):1305-1316. PubMed ID: 34627490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial.
    Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Gori T; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Thalmeier A; Löw A; Holdt L; Teupser D; Ince H; Felix SB; Parma R; Malek L; Horstkotte J; Baylacher M; Schwinger R; Rieber J; Mudra H; Hausleiter J; Huber K; Neumann FJ; Koltowski L; Huczek Z; Mehilli J; Massberg S;
    Thromb Haemost; 2017 Jan; 117(1):188-195. PubMed ID: 27652610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prasugrel dose de-escalation in diabetic patients with acute coronary syndrome receiving percutaneous coronary intervention: results from the HOST-REDUCE-POLYTECH-ACS trial.
    Lee KS; Park KH; Park KW; Rha SW; Hwang D; Kang J; Han JK; Yang HM; Kang HJ; Koo BK; Lee NH; Rhew JY; Chun KJ; Lim YH; Bong JM; Bae JW; Lee BK; Kim SY; Shin WY; Lim HS; Park K; Kim HS
    Eur Heart J Cardiovasc Pharmacother; 2023 Apr; 9(3):262-270. PubMed ID: 36715152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategy of dual antiplatelet therapy for patients with ST-elevation myocardial infarction and non-ST-elevation acute coronary syndromes: A systematic review and network meta-analysis.
    Saito T; Fujisaki T; Aikawa T; Kampaktsis PN; Malik A; Briasoulis A; Takagi H; Wiley J; Slipczuk L; Kuno T
    Int J Cardiol; 2023 Oct; 389():131157. PubMed ID: 37433404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De-escalation from Prasugrel or Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome Managed with Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Clinical Trials.
    Abdelazeem B; Shehata J; Abbas KS; El-Shahat NA; Baral N; Adhikari G; Khan H; Hassan M
    Am J Cardiovasc Drugs; 2022 May; 22(3):287-298. PubMed ID: 34651261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Smoking and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients: a substudy from the randomized TROPICAL-ACS trial.
    Orban M; Trenk D; Geisler T; Rieber J; Hadamitzky M; Gross L; Orban M; Kupka D; Baylacher M; Müller S; Huber K; Koltowski L; Huczek Z; Heyn J; Jacobshagen C; Aradi D; Massberg S; Sibbing D; Hein R;
    Eur Heart J Cardiovasc Pharmacother; 2020 Nov; 6(6):372-381. PubMed ID: 31855244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prasugrel Dose De-escalation Therapy After Complex Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: A Post Hoc Analysis From the HOST-REDUCE-POLYTECH-ACS Trial.
    Hwang D; Lim YH; Park KW; Chun KJ; Han JK; Yang HM; Kang HJ; Koo BK; Kang J; Cho YK; Hong SJ; Kim S; Jo SH; Kim YH; Kim W; Lee SY; Kim YD; Oh SK; Lee JH; Kim HS;
    JAMA Cardiol; 2022 Apr; 7(4):418-426. PubMed ID: 35262625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gender and Outcomes following Guided De-Escalation of Antiplatelet Treatment in Acute Coronary Syndrome Patients: The TROPICAL-ACS Gender Substudy.
    Gross L; Kupka D; Trenk D; Geisler T; Hadamitzky M; Löw A; Orban M; Huber K; Kiss RG; Merkely B; Huczek Z; Beuthner BE; Hein-Rothweiler R; Baylacher M; Rizas K; Massberg S; Aradi D; Sibbing D; Jacobshagen C
    Thromb Haemost; 2019 Sep; 119(9):1527-1538. PubMed ID: 31226717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-Term DAPT and DAPT De-Escalation Strategies for Patients With Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis.
    Kuno T; Watanabe A; Shoji S; Fujisaki T; Ueyama H; Takagi H; Deharo P; Cuisset T; Bangalore S; Mehran R; Stone GW; Kohsaka S; Bhatt DL
    Circ Cardiovasc Interv; 2023 Sep; 16(9):e013242. PubMed ID: 37609850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel de-escalation antiplatelet therapy for patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Li Y; Lei M; Yang Y; An L; Zhou H; Wang J; Zhao Z; Wang X; Nie S; Wang X; Hau WK; Xue Z
    Medicine (Baltimore); 2023 Jul; 102(27):e34153. PubMed ID: 37417626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Age and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: results from the randomized TROPICAL-ACS trial.
    Sibbing D; Gross L; Trenk D; Jacobshagen C; Geisler T; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Parma R; Felix SB; Neumann FJ; Hausleiter J; Baylacher M; Koltowski L; Mehilli J; Huber K; Huczek Z; Aradi D; Massberg S;
    Eur Heart J; 2018 Aug; 39(29):2749-2758. PubMed ID: 29912422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual Antiplatelet Therapy De-Escalation in Stabilized Myocardial Infarction With High Ischemic Risk: Post Hoc Analysis of the TALOS-AMI Randomized Clinical Trial.
    Lee M; Byun S; Lim S; Choo EH; Lee KY; Moon D; Choi IJ; Hwang BH; Kim CJ; Park MW; Choi YS; Kim HY; Yoo KD; Jeon DS; Yim HW; Chang K;
    JAMA Cardiol; 2024 Feb; 9(2):125-133. PubMed ID: 38117483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials.
    Galli M; Benenati S; Franchi F; Rollini F; Capodanno D; Biondi-Zoccai G; Vescovo GM; Cavallari LH; Bikdeli B; Ten Berg J; Mehran R; Gibson CM; Crea F; Pereira NL; Sibbing D; Angiolillo DJ
    Eur Heart J; 2022 Mar; 43(10):959-967. PubMed ID: 34918066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diabetes and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: a pre-specified analysis from the randomised TROPICAL-ACS trial.
    Hein R; Gross L; Aradi D; Rieber J; Hadamitzky M; Merkely B; Huczek Z; Ince H; Hummel A; Baylacher M; Massberg S; Trenk D; Sibbing D;
    EuroIntervention; 2019 Aug; 15(6):e513-e521. PubMed ID: 31012853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.